Cargando…

Intrinsic Susceptibility MRI Identifies Tumors with ALK(F1174L) Mutation in Genetically-Engineered Murine Models of High-Risk Neuroblastoma

The early identification of children presenting ALK(F1174L)-mutated neuroblastoma, which are associated with resistance to the promising ALK inhibitor crizotinib and a marked poorer prognosis, has become a clinical priority. In comparing the radiology of the novel Th-ALK(F1174L)/Th-MYCN and the well...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jamin, Yann, Glass, Laura, Hallsworth, Albert, George, Rani, Koh, Dow-Mu, Pearson, Andrew D. J., Chesler, Louis, Robinson, Simon P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3965493/ https://www.ncbi.nlm.nih.gov/pubmed/24667968 http://dx.doi.org/10.1371/journal.pone.0092886

Ejemplares similares

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on‐target ALK inhibitors in neuroblastoma
por: Tucker, Elizabeth R., et al.
Publicado: (2017)

Multifocal Neuroblastoma and Central Hypoventilation in An Infant with Germline ALK F1174I Mutation
por: Djos, Anna, et al.
Publicado: (2022)

ALK inhibitor resistance in ALK(F1174L)-driven neuroblastoma is associated with AXL activation and induction of EMT
por: Debruyne, D N, et al.
Publicado: (2016)

The mutational landscape of MYCN, Lin28b and ALK(F1174L) driven murine neuroblastoma mimics human disease
por: De Wilde, Bram, et al.
Publicado: (2017)

Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed ALK F1174L-mutated neuroblastoma
por: Liu, Tingting, et al.
Publicado: (2021)

Targeting MYCN and ALK in resistant and relapsing neuroblastoma
por: Tucker, Elizabeth R, et al.
Publicado: (2019)

Oral Metronomic Topotecan Sensitizes Crizotinib Antitumor Activity in ALK(F1174L) Drug-Resistant Neuroblastoma Preclinical Models()
por: Zhang, Libo, et al.
Publicado: (2017)

Pre-clinical imaging of transgenic mouse models of neuroblastoma using a dedicated 3-element solenoid coil on a clinical 3T platform
por: Almeida, Gilberto S, et al.
Publicado: (2017)

Wild-type ALK and activating ALK-R1275Q and ALK-F1174L mutations upregulate Myc and initiate tumor formation in murine neural crest progenitor cells
por: Montavon, Gisèle, et al.
Publicado: (2014)

Expression of the Neuroblastoma-Associated ALK-F1174L Activating Mutation During Embryogenesis Impairs the Differentiation of Neural Crest Progenitors in Sympathetic Ganglia
por: Vivancos Stalin, Lucie, et al.
Publicado: (2019)

The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN
por: Guan, J., et al.
Publicado: (2016)

Oncogenic ALK(F1174L) drives tumorigenesis in cutaneous squamous cell carcinoma
por: Gualandi, Marco, et al.
Publicado: (2020)

Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L
por: Najem, Safiullah, et al.
Publicado: (2016)

miRNA Expression Profiling of the Murine TH-MYCN Neuroblastoma Model Reveals Similarities with Human Tumors and Identifies Novel Candidate MiRNAs
por: Terrile, Marta, et al.
Publicado: (2011)

MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma
por: King, David, et al.
Publicado: (2020)

Correction: MYCN expression induces replication stress and sensitivity to PARP inhibition in neuroblastoma
por: King, David, et al.
Publicado: (2023)

Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
por: Tucker, Elizabeth R., et al.
Publicado: (2023)

An Orthopedic Clinic of 1174 A.D.
por: Cravener, Edward K.
Publicado: (1931)

A case of large-cell neuroendocrine carcinoma harboring rare ALK fusion with initial response to the ALK inhibitor crizotinib and acquired F1174L mutation after resistance
por: Wang, Ye, et al.
Publicado: (2019)

Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma
por: Moore, Nathan F., et al.
Publicado: (2014)

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells
por: Berlak, Mareike, et al.
Publicado: (2022)

ALK in Neuroblastoma: Biological and Therapeutic Implications
por: Trigg, Ricky M., et al.
Publicado: (2018)

Primary resistance to first- and second-generation ALK inhibitors in a non-small cell lung cancer patient with coexisting ALK rearrangement and an ALK F1174L-cis-S1189C de novo mutation: A case report
por: Zhao, Jiuzhou, et al.
Publicado: (2022)

ALK mutation dynamics and clonal evolution in a neuroblastoma model exhibiting two ALK mutations
por: Durand, Simon, et al.
Publicado: (2019)

Activating mutations in ALK provide a therapeutic target in neuroblastoma
por: George, Rani E., et al.
Publicado: (2008)

MYCN and mutationally activated ALK synergise in neuroblastoma
Publicado: (2012)

Loss of ALK hotspot mutations in relapsed neuroblastoma
por: Allinson, Lisa M., et al.
Publicado: (2022)

Genomic ALK alterations in primary and relapsed neuroblastoma
por: Rosswog, Carolina, et al.
Publicado: (2023)

Extracellular domain shedding of the ALK receptor mediates neuroblastoma cell migration
por: Huang, Hao, et al.
Publicado: (2021)

ALK ligand ALKAL2 potentiates MYCN‐driven neuroblastoma in the absence of ALK mutation
por: Borenäs, Marcus, et al.
Publicado: (2021)

NeuroD1 promotes neuroblastoma cell growth by inducing the expression of ALK
por: Lu, Fangjin, et al.
Publicado: (2015)

Liu Sung-nien (1174–1224), Sung Dynasty. Lohan (1207)
por: Potter, Polyxeni
Publicado: (2004)

SG-APSIC1174: High-value instrument management: Rigid endoscopes
por: Sirijindadirat, Nanthipha
Publicado: (2023)

Activated Alk triggers prolonged neurogenesis and Ret upregulation providing a therapeutic target in ALK-mutated neuroblastoma
por: Cazes, Alex, et al.
Publicado: (2014)

Entrectinib and other ALK/TRK inhibitors for the treatment of neuroblastoma
por: Pacenta, Holly L, et al.
Publicado: (2018)

5′ ALK Amplification in Neuroblastoma: A Case Report
por: Akhavanfard, Sara, et al.
Publicado: (2021)

Identification of ALK Mutation in Neuroblastoma on the Point of Molecular Heterogeneity
por: Aktaş, Tekincan Çağrı, et al.
Publicado: (2023)

Clinical response of the novel activating ALK-I1171T mutation in neuroblastoma to the ALK inhibitor ceritinib
por: Guan, Jikui, et al.
Publicado: (2018)

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results
por: Goldsmith, Kelly C., et al.
Publicado: (2023)

Data Rates Between the ISR Equipment and the Control System (Runs 1174 and 1175)
por: Kemp, D
Publicado: (1981)

Cannot write session to /tmp/vufind_sessions/sess_of2pmc9s4qnkvb218isugq5cos